ÜBER MICH

IHR HAUTARZT IN WIEN 1030

IHR HAUTARZT IN WIEN 1030

Martina Sanlorenzo MD, PhD

Ein bisschen über mich

Curriculum VItae

dermatologist with dermatoscope

Ich habe Medizin studiert und danach die Ausbildung zur Dermatologin (Hautarzt) gemacht. Neben meiner klinischen Arbeit habe ich mich mit der Forschung befasst und an der Universität Turin in Italien den Doktortitel für Molekularmedizin erhalten.

During my residency I worked for two years at the Department of Dermatology – Department of Dermatology an der University of San Francisco in Kalifornien (USA) gearbeitet.

Darüber hinaus habe ich auch als Klinikerin und Forscherin gearbeitet und ich hatte die Ehre, für meine Forschung mit dem L’Oreal-Unesco Price for Women in Sciencea highly competitive price supporting women in science – for my research in melanoma.

2016 zog ich nach Wien und trat der Gruppe von Prof. Maria Sibilia am Institut für Krebsforschung derMedizinischen Universität Wienbei. Ich fokussierte mich auf die Entwicklung neuer Behandlungsmöglichkeiten für PatientInnen mit Melanom(en).

Ich bin mit einem kroatisch-österreichischen Dermatologen (Dr. Igor Vujic) verheiratet und wir haben zwei wunderschöne aber sehr lebhafte (!) Kinder.

Ich spreche Englisch, Italienisch, Deutsch und Bosnisch/Kroatisch/Serbisch , und ich freue mich immer wenn ich mit meinen Patienten in Ihrer Sprache reden kann.

IHR HAUTARZT IN WIEN 1030

Um einen Termin zu vereinbaren, können Sie uns per Telefon , E-Mail , Nachricht.

Das Team spricht fließend Englisch, Italienisch und Deutsch.

PREISE

  • First poster prize at the 22nd National Congress Italian Melanoma Intergroup (IMI) (November 2016)
  • Eli Lily Grant to attend the 25th European Academy of Dermatology and Venereology (EADV) congress (September 2016)
  • L’Oreal-UNESCO Italy – For Women in Science 2015-2016 Fellowship (June 2016)
  • Euroderm Excellence 2015 (November 2015)
  • 24th European Academy of Dermatology and Venereology (EADV) congress fellowship (October 2015)
  • Society of Investigative Dermatology (SID) Kligman Travel Fellowship (May 2015)
  • SIDeMaST price to attend the 42nd Annual European Society for Dermatological Research (ESDR) Meeting in Venice (February 2012)

WISSENSCHAFTLICHE PUBLIKATIONEN

  • Sanlorenzo M, Vujic I, Gastaldi T, Hammer M, Fari O, de Sa Fernandes C, Csizer A, Monshi B, Rappersberger K, Sibilia M. Combined oral and topical TLR7/8 agonists treatment promotes effective in-situ tumor vaccination and synergizes with PD1 checkpoint blockage. 2021 Mar – submitted
  • Stanganelli I, De Felici MB, Mandel VD, Caini S, Raimondi S, Corso F, Bellerba F, Quaglino P, Sanlorenzo M, Ribero S, Medri M, Farnetani F, Feliciani C, Pellacani G, Gandini S; IMI the Italian Melanoma Intergroup. The association between pesticide use and cutaneous melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):691-708.
  • Posch C, Sanlorenzo M, Ma J, Kim ST, Zekhtser M, Ortiz-Urda S. MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas. Oncotarget. 2018 Oct 9;9(79):34990-34995.
  • Vujic I, Gandini S, Stanganelli I, Fierro MT, Rappersberger K, Sibilia M, Tosti G, Ferrucci PF, Caini S, De Felici MB, Pagliarello C, Quaglino P, Sanlorenzo M; on behalf of IMI, the Italian Melanoma. A meta-analysis of melanoma risk in industrial workers. Melanoma Res. 2020 Jun;30(3):286-296.
  • Ribero S, Malavenda O, Fava P, Astrua C, Marra E, Osella-Abate S, Sanlorenzo M, Caliendo V, Fierro MT, Quaglino P. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Future Oncol. 2018 Sep 10. doi: 10.2217/fon-2018-0386.
  • Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. 2018 Jul 19;8(1):10902.
  • Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody. Clin Cancer Res. 2018 Jul 15;24(14):3377-3385
  • Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. 2017 Oct 1;28(10):2517-2525
  • Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L. Apremilast in psoriasis – a prospective real-world study.  J Eur Acad Dermatol Venereol. 2018 Feb;32(2):254-259.
  • Broganelli P, Ribero S, Castagno I, Ricceri F, Deboli T, Marra E, Tomasini C, Sacerdote C, Osella-Abate S, Sanlorenzo M, Quaglino P, Fierro MT. The large spectrum of spitzoid tumours: a retrospective survival study. G Ital Dermatol Venereol. 2017 Jul 11. doi: 10.23736/S0392-0488.17.05575-4.
  • Sanlorenzo M, Vujic I, De Giorgi V, Tomasini C, Deboli T, Quaglino P, Fierro MT, Broganelli P. Fluorescence-Advanced-Videodermatoscopy (FAV): a new method for in-vivo skin evaluation. Br J Dermatol. 2017 Nov;177(5):e209-e210.
  • Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger K. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317.
  • Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D. Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells. Clin Cancer Res. 2017 May 1;23(9):2277-2288.
  • Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis J Am Acad Dermatol. 2016 Oct;75(4):736-739.
  • Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016 Jul 19;7(29):45916-45925.
  • Ribero S, Balagna E, Sportoletti Baduel E, Picciotto F, Sanlorenzo M, Fierro MT, Quaglino P, Macripo G. Efficacy of electrochemotherapy for eruptive legs keratoacanthomas. Dermatol Ther. 2016 Sep;29(5):345-348.
  • Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. Phospho-proteomic analysis reveals increased CK2α kinase activity in NRAS(Q61) mutant melanoma. J Invest Dermatol. 2016 Oct;136(10):2041-2048.
  • Sanlorenzo M, Vujic I, Posch C, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S. Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics. 2016 Jul 20;144:140-7.
  • Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R, Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.
  • Sanlorenzo M, Vujic I, Ortiz-Urda S. Time-Dependent Measurement of Adverse Events-Reply.  JAMA Dermatol. 2015 Dec 1;151(12):1392-1393.
  • Sanlorenzo M, Ribero S, Osella Abate S, Mariani S, Strignano P, Salizzoni M, Savoia P, Fierro MT, Quaglino P. Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review. G Ital Dermatol Venereol. 2015 Oct 20. [Epub ahead of print]
  • Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz-Urda S. Combined Inhibition of MEK and Plk1 has Synergistic Anti-Tumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015 Oct;135(10):2475-83
  • Ribero S, Gualano MR, Osella-Abate S, Scaioli G, Bert F, Sanlorenzo M, Balagna E, Fierro MT, Macripò G, Sapino A, Siliquini R, Quaglino P. Histological regression in primary melanoma with sentinel lymph node status: a systematic review and meta-analysis. JAMA Dermatol. 2015 Sep 2. doi: 10.1001/jamadermatol.2015.2235.
  • Sanlorenzo M, Osella-Abate S, Ribero S, Marenco F, Nardò T, Fierro MT, Novelli M, Cervetti O, Bernengo MG, Quaglino P. Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. Int J Dermatol. 2015 Sep;54(9):1023-9.
  • Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K,  Ortiz-Urda S. Pembrolizumab cutaneous adverse events and their correlation with disease progression. JAMA Dermatol. 2015 Jul 29.
  • Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, Macripò G, Macrì L, Sapino A, Quaglino P. Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role? Ann Surg Oncol. 2015 Jun;22(6):1967-73
  • Osella-Abate S, Ribero S, Sanlorenzo M, Maule MM, Richiardi L, Merletti F, Tomasini C, Marra E, Macripò G, Fierro MT, Quaglino P. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer. 2015 May 15;136(10):2453-7
  • Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew: UV Measurements in Flying Airplanes.JAMA Dermatol.2015 Apr;151(4):450-2
  • Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, Parodi A, Novelli M, Osella-Abate S, Ribero S, Sanlorenzo M, Ponti R, Fierro MT, Marzano AV, Savoia P. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol. 2015 Mar 24
  • Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K. Mycoplasma pneumoniae-associated mucositis – case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):595-8.
  • Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza Á, Ortiz-Urda S. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015 Feb;17(1):9908.
  • Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew – A Meta-analysis. JAMA Dermatol. 2015 Jan;151(1):51-8.
  • Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20;6(2):969-78.
  • Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1.
  • Sanlorenzo M, Ribero S, Osella-Abate S, Zugna D, Marenco F, Macripò G, Fierro MT, Bernengo MG, Quaglino P. Prognostic differences across sexes in melanoma patients: what has changed from the past? Melanoma Res. 2014 Dec; 24(6):568-76.
  • Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies. Oncotarget. 2014 Sep 15;5(17):7936-44.
  • Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J, Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 7;6(13):7436-42.
  • Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18;110(6):1427-32.
  • Sanlorenzo M, Ribero S, Osella-Abate S, Balagna EM, Caliendo V, Macripò G, Bernengo MG, Quaglino P. Melanoma in younger patients under 20 years. G Ital Dermatol Venereol. 2013 Dec;148(6):667-72.
  • Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G , Tomasini C, Senetta R, Macripò G, Bernengo MG, Quaglino P. Favourable prognostic role of regression of primary melanoma in stage I-II AJCC patients. Br J Dermatol. 2013 Dec;169(6):1240-5.
  • Ribero S, Quaglino P, Osella-Abate S, Sanlorenzo M, Senetta R, Savoia P, Macrì L, Macripò G, Sapino A, Bernengo MG. Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes. J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1132-7.

IHR HAUTARZT IN WIEN 1030

Um einen Termin zu vereinbaren, können Sie uns per Telefon , E-Mail , Nachricht oder Online erreichen.

Das Team spricht fließend Englisch, Italienisch und Deutsch.

EINE NACHRICHT SENDEN

Mit dem Klick auf SENDEN erklären Sie sich damit einverstanden, von der Ordination von Dr. Sanlorenzo telefonisch oder per Email kontaktiert zu werden, und dass Ihre Personaldaten gemäß dem geltenden Datenschutzgesetz (DSG) aufbewahrt werden.

%%footer%%